Reported Standalone quarterly numbers for Alembic Pharmaceuticals are:Net Sales at Rs 1,235.77 crore in December 2020 up 17.43% from Rs. 1,052.36 crore in December 2019.
Quarterly Net Profit at Rs. 277.35 crore in December 2020 up 19.97% from Rs. 231.19 crore in December 2019.
EBITDA stands at Rs. 374.46 crore in December 2020 up 16.51% from Rs. 321.40 crore in December 2019.
Alembic Pharma EPS has increased to Rs. 14.11 in December 2020 from Rs. 12.26 in December 2019.
Alembic Pharma shares closed at 980.05 on January 20, 2021 (NSE) and has given -3.10% returns over the last 6 months and 63.78% over the last 12 months.
| Alembic Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'20 | Sep'20 | Dec'19 | | Net Sales/Income from operations | 1,235.77 | 1,400.01 | 1,052.36 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 1,235.77 | 1,400.01 | 1,052.36 | | EXPENDITURE | | Consumption of Raw Materials | 325.55 | 322.66 | 233.05 | | Purchase of Traded Goods | 74.61 | 85.72 | 50.04 | | Increase/Decrease in Stocks | -91.43 | -63.82 | 1.81 | | Power & Fuel | -- | -- | -- | | Employees Cost | 236.53 | 250.36 | 204.62 | | Depreciation | 38.21 | 36.71 | 34.31 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 318.76 | 348.94 | 241.73 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 333.54 | 419.44 | 286.80 | | Other Income | 2.71 | 2.84 | 0.29 | | P/L Before Int., Excpt. Items & Tax | 336.25 | 422.28 | 287.09 | | Interest | 2.21 | 2.33 | 6.93 | | P/L Before Exceptional Items & Tax | 334.04 | 419.95 | 280.16 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 334.04 | 419.95 | 280.16 | | Tax | 56.69 | 71.65 | 48.97 | | P/L After Tax from Ordinary Activities | 277.35 | 348.30 | 231.19 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 277.35 | 348.30 | 231.19 | | Equity Share Capital | 39.31 | 39.31 | 37.70 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 14.11 | 18.02 | 12.26 | | Diluted EPS | 14.11 | 18.02 | 12.26 | | EPS After Extra Ordinary | | Basic EPS | 14.11 | 18.02 | 12.26 | | Diluted EPS | 14.11 | 18.02 | 12.26 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|